Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
10x Genomics, Inc. filings document regulatory disclosures for a Nasdaq-listed life science technology company with Class A common stock. Form 8-K reports furnish quarterly and annual operating results, selected preliminary results and business updates related to single cell and spatial biology platforms, including instruments, consumables, software and product launches.
The filing record also includes definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items, as well as Form 8-K disclosure for executive officer transitions and related compensation arrangements. These documents describe TXG's public-company governance, registered security, financial reporting events and material corporate updates.
TXG affiliate files a Form 144 proposing sales of Class A Common stock. The filing lists multiple vested RSU lots tied to issuer vesting events, including 16,152; 4,879; 3,265; 3,723; 8,156; and 4,977 shares. The filing lists JP Morgan Securities LLC as broker and Nasdaq as the market.
10x Genomics, Inc. director Sarah A. Teichmann reported an open-market sale of 7,579 shares of Class A Common Stock at $19.41 per share. After this transaction, she directly holds 26,780 shares. The sale was executed under her pre-arranged Rule 10b5-1 trading plan.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported an open-market sale of 9,632 shares of Class A common stock on February 23, 2026 at an average price of $18.5764 per share. The shares were sold to cover tax withholding obligations related to vesting restricted stock units.
After this transaction, Saxonov directly held 1,061,924 Class A shares. In addition, indirect holdings as trustee included 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust.
10x Genomics Chief Financial Officer Adam Taich reported an open-market sale of 8,968 shares of Class A Common Stock. The transaction took place on February 23, 2026 at an average price of $18.5764 per share, and was conducted to cover tax withholding obligations related to vesting restricted stock units.
After this transaction, Taich directly owned 288,417 shares of 10x Genomics Class A Common Stock.
10x Genomics, Inc. director and officer Benjamin J. Hindson reported an open-market sale of 7,826 shares of Class A common stock at an average price of $18.5764 per share. According to the filing, the shares were sold to cover tax withholding obligations from vesting restricted stock units. After this transaction, Hindson directly owns 424,779 shares.
TXG filed a Form 144 reporting a proposed sale of common stock by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists restricted stock lots of 3,740 shares dated 11/21/2025 and 3,839 shares dated 08/21/2025.
Benjamin J. Hindson submitted a Form 144 reporting a proposed sale of 8,301 shares of common stock, listed with Morgan Stanley Smith Barney LLC and dated 02/23/2026. The filing also records a prior sale of 8,283 shares on 11/24/2025. The securities to be sold reference a Restricted Stock Unit Grant dated 02/21/2026.
TXG files a Form 144 disclosing an intended sale of 25,784 shares of Common Stock tied to a Restricted Stock Unit Grant dated 02/21/2026. The notice also reports an earlier sale of 13,261 shares on 11/24/2025 for $251,936.46.
TXG files a Form 144 reporting a proposed sale of Common Stock. The notice lists 23,767 shares associated with a Restricted Stock Unit grant dated 02/21/2026. The filing also discloses an earlier sale of 11,888 shares on 11/24/2025 by Adam Taich.
10x Genomics, Inc. is a life sciences technology company focused on single cell, spatial and in situ analysis through its Chromium, Visium and Xenium platforms, supported by software like Cell Ranger, Loupe Browser and Xenium Explorer. In 2025 it acquired Scale Biosciences, adding QuantumScale single cell kits.
For the year ended December 31, 2025, revenue was $642.8 million, up 5% from $610.8 million in 2024, while net loss narrowed to $43.5 million from $182.6 million. The company sold 1,007 instruments and 424,000 consumable reactions in 2025 and estimates a total addressable market above $21 billion. Key risks include dependence on academic and government research funding (notably NIH), intense competition in genomics tools, potential pricing pressure, trade and tariff exposure, and execution challenges in entering clinical and diagnostic markets.